Merck & Co., Inc. is looking to see how the US Food and Drug Administration’s openness to using biomarkers in Alzheimer’s disease drug development may affect its programs.
During its 29 July second quarter earnings call, an analyst asked about the company’s interest in expanding its neuroscience footprint now that there is apparently a more favorable environment at the FDA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?